Stockscreener 앱 받기
2.79
4.45%
-0.13
전일 마감가:
$2.92
열려 있는:
$2.85
하루 거래량:
126.71K
Relative Volume:
0.38
시가총액:
$3.84M
수익:
$12.31M
순이익/손실:
$-5.08M
주가수익비율:
-1.8355
EPS:
-1.52
순현금흐름:
$-5.20M
1주 성능:
-1.76%
1개월 성능:
-6.69%
6개월 성능:
-29.30%
1년 성능:
-15.45%
1일 변동 폭
$2.73
$2.92
1주일 범위
$2.70
$3.138
52주 변동 폭
$2.52
$9.374
소노마 파머 Stock (SNOA) Company Profile
명칭
Sonoma Pharmaceuticals Inc
전화
800-759-9305
주소
5445 CONESTOGA COURT, SUITE 150, BOULDER, CA
SNOA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SNOA
Sonoma Pharmaceuticals Inc
|
2.79 | 3.84M | 12.31M | -5.08M | -5.20M | -1.52 |
|
ZTS
Zoetis Inc
|
176.74 | 80.59B | 9.15B | 2.43B | 2.31B | 4.92 |
|
HLN
Haleon Plc Adr
|
9.72 | 44.17B | 14.26B | 1.55B | 0 | 0.3327 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.57 | 42.61B | 30.27B | 1.93B | 3.45B | 0.444 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.57 | 18.77B | 16.77B | -959.00M | 1.37B | -2.00 |
|
VTRS
Viatris Inc
|
13.22 | 15.73B | 15.05B | -883.30M | 1.89B | 1.53 |
소노마 파머 주식(SNOA)의 최신 뉴스
Despite Fast-paced Momentum, Sonoma Pharmaceuticals (SNOA) Is Still a Bargain Stock - Yahoo Finance
Sonoma Pharmaceuticals (STU:O8Z) Growth Rank : 2 (As of Nov. 26, 2024) - GuruFocus.com
Eye Care Product Lines - Trend Hunter
Alkermes (ALKS) Stock Surges Over 5% Amid Strong Financial Perfo - GuruFocus.com
Sonoma Pharmaceuticals, Inc. Receives New FDA 510(K) Clearance for Microcyn(R)-Based Wound Care Hydrogel - Marketscreener.com
Scar Treatment Market Detailed In New Research Report 2024 | - openPR
Sonoma Pharmaceuticals ends agreement with EMC Pharma - Investing.com
Merck (MRK) Stock Surges Amid Industry Layoff Trends - GuruFocus.com
Sonoma Pharmaceuticals ends agreement with EMC Pharma By Investing.com - Investing.com Australia
Sonoma Pharmaceuticals Announces Relaunch of Prescription Dermatology and Eye Care Product Lines in - PharmiWeb.com
Amarin (AMRN) Stock Surges Amid Mixed Industry Performance - GuruFocus.com
Sonoma Pharmaceuticals Announces Relaunch of Prescription Dermatology and Eye Care Product Lines in the United States - AccessWire
Sonoma Pharmaceuticals, Inc. Announces Relaunch of Prescription Dermatology and Eye Care Product Lines in the United States - Marketscreener.com
Sonoma Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2024 - Marketscreener.com
U.S. shares lower at close of trade; Dow Jones Industrial Average down 0.86% - MSN
Animal Wound Care Market to Exhibit a Remarkable CAGR of 7.9% - openPR
AMGN Stock Drops 5% Amid Industry Decline and Earnings Report - GuruFocus.com
Siga Technologies (SIGA) Sees Significant Stock Decline Amidst P - GuruFocus.com
Sonoma Pharmaceuticals gains FDA clearance for hydrogel By Investing.com - Investing.com Australia
Sonoma Pharmaceuticals (NASDAQ:SNOA) Share Price Passes Above Two Hundred Day Moving Average – Here’s Why - Defense World
Sonoma Pharmaceuticals gains FDA clearance for hydrogel - Investing.com India
Sonoma Pharmaceuticals Receives New FDA 510(k) Clearance for Microcyn(R)-based Wound Care Hydrogel - AccessWire
Pre-market Movers: REVB, CDIO, SMLR, DWTX... - RTTNews
Sonoma Pharmaceuticals Second Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
Sonoma Pharmaceuticals Inc. (SNOA) Quarterly 10-Q Report - Quartz
Sonoma Pharmaceuticals Inc (SNOA) Quarterly 10-Q Report - Quartzy
Sonoma Pharmaceuticals Reports Second Fiscal Quarter 2025 Financial Results - AccessWire
Certain Options of Sonoma Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 29-JAN-2020. - Marketscreener.com
Certain Restricted Stock Units of Sonoma Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 29-JAN-2020. - Marketscreener.com
Certain Warrants of Sonoma Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 29-JAN-2020. - Marketscreener.com
Certain Preferred stock of Sonoma Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 29-JAN-2020. - Marketscreener.com
Sonoma Pharmaceuticals to Exhibit at MEDICA 2024 in Düsseldorf - AccessWire
Sonoma Pharmaceuticals, Inc. to Exhibit At MEDICA 2024 in Dusseldorf - Marketscreener.com
Sonoma Pharmaceuticals (SNOA) Surges Amid Positive Analyst Ratin - GuruFocus.com
Unveiling the Future: Animal Wound Care Market to USD 1.24 BILLION IN 2023, Forecast by 2030, Featuring a C... - WhaTech
Sonoma Pharmaceuticals Announces Expanded Partnership with Global Healthcare Distributor for Distribution of Wound Care Products in Canada - AccessWire
Sonoma Pharmaceuticals to Present at Danisavage Financial Strategies, and LD Micro Main Event XVII Investor Conferences - AccessWire
Scar Treatment Market to See Booming Growth 2024-2031 | Bausch - openPR
Keloid Treatment Market Latest Report 2023-2031 - InsightAce Analytic
Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) Stock's 43% Dive Might Signal An Opportunity But It Requires Some Scrutiny - Simply Wall St
Recent Developments in the Eye Skin Care Market - openPR
Keloid Treatment Market: Insights Predicting a $4.72 Billion Valuation by 2031 - WhaTech
Hypertrophic Scar Treatment Market Growth, Trends, and Industry Share Analysis (2024-2032) - News in Assen
Sonoma Pharmaceuticals (SNOA) Shares Surge Amid Positive Market Activity - GuruFocus.com
Sonoma Pharmaceuticals (NASDAQ:SNOA) Stock Price Crosses Above Two Hundred Day Moving AverageTime to Sell? - MarketBeat
Williams-Sonoma, Inc. (WSM) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
소노마 파머 (SNOA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.83%
1.03%
자본화:
|
볼륨(24시간):